Anti-GATA3 CE/IVD for IHC - Gynecological pathology

Anti-GATA3 CE/IVD for IHC - Gynecological pathology

Anti-GATA3 CE/IVD IHC reagents provide reproducible nuclear staining for detection of GATA-binding protein 3 (GATA3) in formalin-fixed paraffin-embedded (FFPE) tissue — supporting diagnostic classification, origin assignment and research in breast and selected gynecological tumors.

Why GATA3 matters in breast & gynecologic pathology

  • GATA3 is a zinc-finger transcription factor integral to mammary luminal epithelial differentiation; it is expressed in the majority of luminal breast carcinomas and is frequently used as a sensitive marker of breast origin in carcinoma of unknown primary.
  • GATA3 also shows high expression in urothelial carcinoma and variable/occasional expression in some gynecological tumors (e.g., a subset of endometrioid endometrial and ovarian carcinomas); careful interpretation within an IHC panel is required.

Intended use & clinical utility

  • Intended use: qualitative detection of GATA3 protein by IHC on FFPE tissue to assist pathologists with tumor classification, differential diagnosis and origin assignment in breast and gynecologic pathology.
  • Diagnostic roles:
    • Support confirmation of primary breast carcinoma (particularly luminal subtypes) and distinction from metastases of non-breast origin.
    • Serve as part of an IHC panel to resolve differential diagnoses involving urothelial, breast and selected gynecologic tumors.

Key technical considerations for laboratories and researchers

  • Clone selection & cross-validation: choose a clone with peer-reviewed performance data and validate in your setting against known positive/negative cases.
  • Panel context: interpret GATA3 with ER/PR, mammaglobin, GCDFP-15, urothelial markers (e.g., uroplakin, CK7/CK20) to increase diagnostic specificity.
  • Reporting: record percentage of positive tumor nuclei, staining intensity and note any heterogeneous or focal patterns; provide contextual interpretation in pathology reports.

Benefits for research & clinical practice

  • Reduced variability: CE-IVD IHC reagents reduce inter-laboratory variability and support reproducible translational research datasets.
  • Enhanced diagnostic confidence: sensitive nuclear staining for GATA3 improves ability to identify luminal breast tumors and to include/exclude breast origin when assessing metastases or poorly differentiated carcinomas.

 

Breast carcinoma
Breast carcinoma

 

Search result : 3 product found

Refine your search :

RUO
CE/IVD
NEW
  • Unconjugated 3
  • human 3
  • mouse 3
  • Primary antibody
  • IHC 3
  • IHC583 3
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT